Background
==========

Hepatocellular carcinoma (HCC) is the most common liver cancer \[[@b1-anntransplant-23-524],[@b2-anntransplant-23-524]\], and it is the third highest cause of cancer-associated deaths worldwide \[[@b3-anntransplant-23-524]\]. HCC has become a considerable global health issue. Currently, liver transplantation (LT) is an ideal treatment for early stage HCC patients \[[@b4-anntransplant-23-524],[@b5-anntransplant-23-524]\]. LT treats both the tumor and concealed liver disease, and it has the highest cure rate among treatments \[[@b5-anntransplant-23-524],[@b6-anntransplant-23-524]\]. In recent years, transplant centers have experienced a consistent growth in the number of patients with HCC who are contenders for LT. LT for HCC constitutes 15--50% of all LTs performed in most transplant centers \[[@b7-anntransplant-23-524],[@b8-anntransplant-23-524]\]. Even though LT is an exceptional treatment option for HCC patients, the number of patients waiting for an LT surpasses the number of available donors \[[@b9-anntransplant-23-524],[@b10-anntransplant-23-524]\]. Thus, not all patients with HCC are a considered for primary liver transplantation (PLT).

The shortage of donors compared with the number of patients in need of a transplant is a serious and a persisting problem worldwide. To overcome long waiting lists, disease progression, and the dropout rate for LT, different "bridging" therapies, such as liver resection (LR) \[[@b11-anntransplant-23-524]\], radioembolization \[[@b12-anntransplant-23-524]\], radiofrequency ablation \[[@b13-anntransplant-23-524]\], and transarterial chemoembolization \[[@b14-anntransplant-23-524]\], have been used if waiting time for LT is more than 6 months. Majno et al. was the first to suggest salvage liver transplantation (SLT), which refers to an LT done after LR for HCC or crumbling of liver function after LR \[[@b15-anntransplant-23-524]\]. Since then, several studies have shown SLT is an effective approach for patients with recurrent HCC or crumbling of liver function after LR \[[@b11-anntransplant-23-524],[@b16-anntransplant-23-524]\]. However, some studies have shown negative results for SLT compared to PLT \[[@b17-anntransplant-23-524],[@b18-anntransplant-23-524]\], mainly related to surgical difficulties due to adhesions, increased rate of post-transplant complications, and poor long-term outcomes. Thus, SLT remains a controversial approach for many surgeons.

To our knowledge, only a few systematic evaluations of the short-term and long-term outcomes between SLT and PLT have been performed, and these evaluations have included only a few studies and a small total number of patients. Therefore, the main aim of this meta-analysis was to include more studies and a larger sample size in the comparison of SLT and PLT for short-term and long-term outcomes. Our study results may help physicians select which approach would likely have a major survival benefit for HCC patients and allow physicians to efficiently utilize a limited source of liver donors.

Material and Methods
====================

Search strategy
---------------

Eligible studies for this systematic review and meta-analyses were identified by 2 authors (DY and WC) independently, following an a priori established protocol using the PubMed/MEDLINE, Embase, and Cochrane Library databases, and combining Medical Subject Headings (MeSH) and non-MeSH terms: liver transplantation, salvage liver transplantation, salvage transplantation, liver resection, PLT, SLT, hepatic resection, hepatectomy, hepatocellular carcinoma, tumor recurrence, primary liver carcinoma, and HCC. In addition, relevant bibliographical lists of reviews were searched to identify other relevant studies. After an initial screening, abstracts, duplicate articles, or unpublished studies were excluded. The meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines \[[@b19-anntransplant-23-524]\].

Study selection
---------------

Considering that this systematic review investigated data with respect to outcomes, both retrospective and prospective studies were considered eligible. The goal was to guarantee the quality of the systematic review by only considering complete articles and not abstracts. We established a priori defined eligibility criteria for selection of studies. The inclusion criteria included: 1) study had a definition of SLT and PLT with SLT referred to as an LT done after LR for HCC or crumbling of liver function after LR, and PLT characterized as an LT done for HCC without any prior LR. 2) Study that had patients with HCC and compared short-term and long-term results between SLT and PLT. 3) Study had sufficient data to conduct a meta-analysis.

The exclusion criteria included: 1) study without human subjects. 2) Study containing advance disease stage or extrahepatic metastases. 3) Study with no comparison between SLT and PLT. 4) Study with a multi-organ transplant. 5) Study with patients older than 70 years. 6) Study with duplicate data from the same institution. 7) Publication such as review article, editorial, case report, conference report, or letter.

Data extraction
---------------

All data were extracted according to the study selection criteria in a systematize data abstraction form in Microsoft Excel 2007 (Microsoft Corp.). The extracted data included the name of the first author, study characteristics (publication year, country, and study design), participant characteristics (average age of the recipients, sample size of SLT and PLT within and beyond Milan criteria, and sample size of SLT and PLT according to donor types), pre-transplant Model for End-Stage Liver Disease (MELD) score, pre-transplant alpha-fetoprotein (AFP) level, pre-transplant tumor status, pre-transplant "bridging" therapies, the duration of follow-up, and outcomes (biliary complications, sepsis, postoperative bleeding, vascular complications, perioperative mortality, OS, and DFS). Moreover, in case of insufficient data, investigators were approached to collect more relevant results. Conflicts in data extraction were resolved by discussion or consensus with a third reviewer.

Quality assessment
------------------

The quality of included studies was evaluated with the Newcastle-Ottawa scale (NOS) \[[@b20-anntransplant-23-524]\]. The scale is comprised of 3 assessment factors: 1) assessment of a selection of the study groups; 2) comparability of 2 groups; and 3) outcome assessment. The NOS ranges from 0 to 9. Studies with scores 7 were thought to be high quality, 4--6 moderate quality, and less than 4 low quality ([Table 1](#t1-anntransplant-23-524){ref-type="table"}).

Statistical analysis
--------------------

All results are accounted for as in the original articles and were double-checked. A meta-analysis was carried out with RevMan Version 5.3 (Review Manager, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). Outcomes are calculated as pooled odds ratios (ORs) and standard mean difference (SMD) with corresponding 95% confidence intervals (CIs). Fixed-effect or random-effect models were utilized to compute summary estimates based on the evaluation of heterogeneity. Overall effects were evaluated using the Z-test; heterogeneity was tested using Cochran's χ^2^ test. The I^2^ statistic was used to evaluate heterogeneity, which was characterized as low, moderate, or high (\>25%, \>50%, and \>75% respectively) \[[@b21-anntransplant-23-524]\]. Two-sided *P*-values less than 0.05 were considered significant.

Outcome measures
----------------

Pre-transplant parameters examined were: MELD score, AFP level, bridging therapies, and tumor status. Postoperative outcome parameters examined were: biliary complications (includes biliary strictures or fistulas), sepsis, postoperative bleeding, vascular complications, and operative mortality. Long-term outcomes were: 1-year, 3-year, and 5-year OS and DFS rates for patients within and beyond Milan criteria, and donor types along with follow-up period.

Results
=======

Study search and included studies
---------------------------------

The database search identified 3714 references for assessment ([Figure 1](#f1-anntransplant-23-524){ref-type="fig"}) of which 154 full-text articles were assessed for eligibility; of these, 134 articles were excluded (121 did not meet inclusion criteria and 13 had insufficient data). The remaining 20 retrospective studies between 2003 and 2017 were eligible according to our inclusion criteria and were included in this meta-analysis \[[@b11-anntransplant-23-524],[@b16-anntransplant-23-524]--[@b18-anntransplant-23-524],[@b22-anntransplant-23-524]--[@b37-anntransplant-23-524]\], with a total of 9879 patients included (SLT=1306 patients and PLT=8573 patients) ([Table 2](#t2-anntransplant-23-524){ref-type="table"}).

Meta-analysis
-------------

### Pre-transplant MELD score between SLT and PLT

To assess the outcome measurement of MELD scores, a total of 1308 patients were included from 7 studies \[[@b16-anntransplant-23-524],[@b23-anntransplant-23-524],[@b26-anntransplant-23-524]--[@b28-anntransplant-23-524],[@b31-anntransplant-23-524],[@b32-anntransplant-23-524]\]. The χ^2^ test revealed *P*=0.07 and I^2^=48%; meta-analysis using a fixed effect model revealed that SLT had significantly lower MELD score than that of PLT (SMD: −0.22, 95% CI: −0.37 to −0.07, *P*=0.004) ([Figure 2A](#f2-anntransplant-23-524){ref-type="fig"}).

### Pre-transplant AFP level between SLT and PLT

To assess the outcome measurement of AFP level, a total of 8382 patients were included from 7 studies \[[@b17-anntransplant-23-524],[@b18-anntransplant-23-524],[@b26-anntransplant-23-524],[@b27-anntransplant-23-524],[@b30-anntransplant-23-524],[@b32-anntransplant-23-524],[@b37-anntransplant-23-524]\]. The χ^2^ test revealed *P*=0.002 and I^2^=71%; meta-analysis using a random effect model revealed that SLT had a significantly lower AFP level than that of PLT (SMD: −0.27, 95% CI: −0.51 to −0.04, *P*=0.02) ([Figure 2B](#f2-anntransplant-23-524){ref-type="fig"}).

### Pre-transplant tumor status between SLT and PLT

Our meta-analysis found that the maximum tumor diameter and the number of tumors \>3 cm was significantly higher in PLT patients than in SLT patients: (SMD: −0.51, 95% CI: −0.95 to −0.08, *P*=0.02, [Figure 3A](#f3-anntransplant-23-524){ref-type="fig"}) \[[@b17-anntransplant-23-524],[@b22-anntransplant-23-524],[@b26-anntransplant-23-524],[@b30-anntransplant-23-524],[@b32-anntransplant-23-524],[@b35-anntransplant-23-524],[@b37-anntransplant-23-524]\], and (OR: 0.59, 95% CI: 0.41 to 0.86, *P*=0.006, [Figure 3B](#f3-anntransplant-23-524){ref-type="fig"}) \[[@b17-anntransplant-23-524],[@b26-anntransplant-23-524],[@b27-anntransplant-23-524],[@b33-anntransplant-23-524],[@b34-anntransplant-23-524]\] respectively. However, SLT patients had significantly higher numbers of nodules than PLT patients (SMD: 0.57, 95% CI: 0.17 to 0.97, *P*=0.005, [Figure 3C](#f3-anntransplant-23-524){ref-type="fig"}) \[[@b17-anntransplant-23-524],[@b22-anntransplant-23-524],[@b26-anntransplant-23-524],[@b30-anntransplant-23-524],[@b32-anntransplant-23-524],[@b35-anntransplant-23-524],[@b37-anntransplant-23-524]\]. But, the meta-analysis of \>3 nodules was not significantly different between the 2 groups (OR: 2.36, 95% CI: 0.86 to 6.46, *P*=0.09, [Figure 3D](#f3-anntransplant-23-524){ref-type="fig"}) \[[@b16-anntransplant-23-524],[@b17-anntransplant-23-524],[@b33-anntransplant-23-524],[@b34-anntransplant-23-524]\].

### Pre-transplant therapy between SLT and PLT

While looking at pre-transplant therapy between SLT patients and PLT patients in the included studies, we found no significant difference between the 2 groups (OR: 1.78, 95% CI: 0.87 to 3.62, *P*=0.11, [Figure 4A](#f4-anntransplant-23-524){ref-type="fig"}) \[[@b16-anntransplant-23-524],[@b17-anntransplant-23-524],[@b26-anntransplant-23-524],[@b28-anntransplant-23-524],[@b30-anntransplant-23-524],[@b33-anntransplant-23-524],[@b34-anntransplant-23-524]\].

Follow-up period between SLT patients and PLT patients
------------------------------------------------------

While looking at the follow-up period between SLT patients and PLT patients in the included studies we found that there was no significant difference between the 2 groups (SMD: −0.25, 95% CI: −0.56 to 0.05, *P*=0.10, [Figure 4B](#f4-anntransplant-23-524){ref-type="fig"}) \[[@b16-anntransplant-23-524]--[@b18-anntransplant-23-524],[@b22-anntransplant-23-524]--[@b24-anntransplant-23-524],[@b26-anntransplant-23-524]--[@b31-anntransplant-23-524],[@b34-anntransplant-23-524]--[@b37-anntransplant-23-524]\].

OS outcomes between SLT and PLT
-------------------------------

To assess the outcome measurement of 1-year OS, a total of 9725 patients were included from 19 studies \[[@b16-anntransplant-23-524]--[@b18-anntransplant-23-524],[@b22-anntransplant-23-524]--[@b37-anntransplant-23-524]\]. The χ^2^ test revealed *P*=0.48 and I^2^=0%; meta-analysis using a fixed effect model revealed that the SLT group (74.30%) had superior 1-year OS rate compared to the PLT group (77.01%), which was statistically significant (OR: 0.86, 95% CI: 0.75 to 0.98, *P*=0.03) [Figure 5A](#f5-anntransplant-23-524){ref-type="fig"}.

To assess the outcome measurement of the 3-year OS rate, a total of 9649 patients were included from 18 studies \[[@b16-anntransplant-23-524]--[@b18-anntransplant-23-524], [@b22-anntransplant-23-524]--[@b30-anntransplant-23-524],[@b32-anntransplant-23-524]--[@b37-anntransplant-23-524]\]. The χ^2^ test revealed *P*=0.48 and I^2^=0%; meta-analysis using a fixed effect model revealed that the SLT group (55.69%) had a superior 3-year OS rate compared to the PLT group (59.07%), which was statistically significant (OR: 0.85, 95% CI: 0.76 to 0.96, *P*=0.01) [Figure 5B](#f5-anntransplant-23-524){ref-type="fig"}.

To assess the outcome measurement of the 5-year OS rate, a total of 9756 patients were included from 18 studies \[[@b11-anntransplant-23-524],[@b16-anntransplant-23-524]--[@b18-anntransplant-23-524],[@b22-anntransplant-23-524]--[@b30-anntransplant-23-524],[@b32-anntransplant-23-524]--[@b36-anntransplant-23-524]\]. The χ^2^ test revealed *P*=0.37 and I^2^=7%; meta-analysis using a fixed effect model revealed that the SLT group (48.67%) had a superior 5-year OS rate compared to the PLT group (52.32%), which was statistically significant (OR: 0.85, 95% CI: 0.76 to 0.96, *P*=0.009) [Figure 5C](#f5-anntransplant-23-524){ref-type="fig"}.

Data was classified according to donor type: DDLT and LDLT. In DDLT recipients, there was no significant difference in 1-year OS rate (OR: 0.93, 95% CI: 0.80 to 1.09, *P*=0.40, [Figure 6A](#f6-anntransplant-23-524){ref-type="fig"}) \[[@b16-anntransplant-23-524],[@b17-anntransplant-23-524],[@b22-anntransplant-23-524],[@b24-anntransplant-23-524]--[@b27-anntransplant-23-524],[@b29-anntransplant-23-524],[@b30-anntransplant-23-524],[@b33-anntransplant-23-524],[@b35-anntransplant-23-524]--[@b37-anntransplant-23-524]\] and 3-year OS rate (OR: 0.89, 95% CI: 0.78 to 1.02*, P*=0.08, [Figure 6B](#f6-anntransplant-23-524){ref-type="fig"}) \[[@b16-anntransplant-23-524]--[@b18-anntransplant-23-524], [@b22-anntransplant-23-524],[@b24-anntransplant-23-524]--[@b27-anntransplant-23-524],[@b29-anntransplant-23-524],[@b30-anntransplant-23-524],[@b33-anntransplant-23-524],[@b35-anntransplant-23-524]--[@b37-anntransplant-23-524]\] between the SLT group and the PLT group. However, 5-year OS rate was superior in the SLT group compared to the PLT group (OR: 0.81, 95% CI: 0.71 to 0.92, *P*=0.001, [Figure 6C](#f6-anntransplant-23-524){ref-type="fig"}) \[[@b16-anntransplant-23-524],[@b17-anntransplant-23-524],[@b22-anntransplant-23-524],[@b24-anntransplant-23-524]--[@b27-anntransplant-23-524],[@b29-anntransplant-23-524],[@b30-anntransplant-23-524],[@b33-anntransplant-23-524],[@b35-anntransplant-23-524],[@b36-anntransplant-23-524]\]. In LDLT recipients, SLT had superior 1-year, 3-year, and 5-year OS rates compared to PLT: (OR: 0.49, 95% CI: 0.26 to 0.95, *P*=0.03, [Figure 7A](#f7-anntransplant-23-524){ref-type="fig"}) \[[@b23-anntransplant-23-524],[@b30-anntransplant-23-524],[@b32-anntransplant-23-524],[@b34-anntransplant-23-524]\], (OR: 0.47, 95% CI: 0.28 to 0.79*, P*=0.004, [Figure 7B](#f7-anntransplant-23-524){ref-type="fig"}) \[[@b23-anntransplant-23-524],[@b30-anntransplant-23-524],[@b32-anntransplant-23-524],[@b34-anntransplant-23-524]\], and (OR: 0.43, 95% CI: 0.26 to 0.71*, P*=0.0009, [Figure 7C](#f7-anntransplant-23-524){ref-type="fig"}) \[[@b23-anntransplant-23-524],[@b30-anntransplant-23-524],[@b32-anntransplant-23-524],[@b34-anntransplant-23-524]\], respectively.

Additionally, data were classified according to Milan criteria: within Milan criteria and beyond Milan criteria. In patients within Milan criteria, the meta-analysis revealed no statistically significant difference for 1-year, 3-year, and 5-year OS rates between the SLT group and the PLT group: (OR: 0.68, 95% CI: 0.44 to 1.04*, P*=0.08, [Figure 8A](#f8-anntransplant-23-524){ref-type="fig"}) \[[@b16-anntransplant-23-524],[@b18-anntransplant-23-524],[@b22-anntransplant-23-524],[@b23-anntransplant-23-524],[@b25-anntransplant-23-524]--[@b27-anntransplant-23-524],[@b31-anntransplant-23-524],[@b33-anntransplant-23-524],[@b33-anntransplant-23-524],[@b36-anntransplant-23-524]\], (OR: 0.78, 95% CI: 0.55 to 1.11, *P*=0.17, [Figure 8B](#f8-anntransplant-23-524){ref-type="fig"}) \[[@b16-anntransplant-23-524],[@b18-anntransplant-23-524],[@b22-anntransplant-23-524],[@b23-anntransplant-23-524], [@b25-anntransplant-23-524]--[@b27-anntransplant-23-524],[@b33-anntransplant-23-524],[@b35-anntransplant-23-524],[@b36-anntransplant-23-524]\], and (OR: 0.75, 95% CI: 0.40 to 1.42*, P*=0.38, [Figure 8C](#f8-anntransplant-23-524){ref-type="fig"}) \[[@b11-anntransplant-23-524],[@b16-anntransplant-23-524],[@b18-anntransplant-23-524],[@b22-anntransplant-23-524],[@b23-anntransplant-23-524],[@b25-anntransplant-23-524]--[@b27-anntransplant-23-524],[@b33-anntransplant-23-524],[@b35-anntransplant-23-524],[@b36-anntransplant-23-524]\], respectively. Similarly, in patients beyond the Milan criteria, both SLT and PLT showed no significant difference for 1-year, 3-year, and 5-year OS rates: (OR: 0.68, 95% CI: 0.19 to 2.48, *P*=0.56, [Figure 9A](#f9-anntransplant-23-524){ref-type="fig"}) \[[@b18-anntransplant-23-524],[@b29-anntransplant-23-524],[@b31-anntransplant-23-524],[@b37-anntransplant-23-524]\], (OR: 2.07, 95% CI: 0.92 to 4.66*, P*=0.08, [Figure 9B](#f9-anntransplant-23-524){ref-type="fig"}) \[[@b18-anntransplant-23-524],[@b29-anntransplant-23-524],[@b37-anntransplant-23-524]\], and (OR: 2.01, 95% CI: 0.75 to 5.40*, P*=0.17, [Figure 9C](#f9-anntransplant-23-524){ref-type="fig"}) \[[@b18-anntransplant-23-524],[@b29-anntransplant-23-524]\], respectively.

DFS outcomes between SLT patients and PLT patients
--------------------------------------------------

To assess the outcome measurement of 1-year DFS a total of 8868 patients were included from 13 studies \[[@b16-anntransplant-23-524]--[@b18-anntransplant-23-524], [@b26-anntransplant-23-524],[@b28-anntransplant-23-524]--[@b30-anntransplant-23-524],[@b32-anntransplant-23-524]--[@b37-anntransplant-23-524]\]. The χ^2^ test revealed *P*=0.08 and I^2^=38%; meta-analysis using a fixed effect model revealed that the SLT group (67.69%) had superior 1-year DFS rate compared to the PLT group (70.03%), which was statistically significant (OR: 0.86, 95% CI: 0.75 to 0.99, *P*=0.03) [Figure 10A](#f10-anntransplant-23-524){ref-type="fig"}.

To assess the outcome measurement of 3-year DFS, a total of 6910 patients were included from 14 studies \[[@b16-anntransplant-23-524]--[@b18-anntransplant-23-524], [@b22-anntransplant-23-524],[@b26-anntransplant-23-524],[@b28-anntransplant-23-524]--[@b30-anntransplant-23-524],[@b32-anntransplant-23-524]--[@b37-anntransplant-23-524]\]. The χ^2^ test revealed *P*=0.02 and I^2^=50%; meta-analysis using a random-effect model revealed that the SLT group (57.02%) had superior 3-year DFS rate compared to the PLT group (74.08%), which was statistically significant (OR: 0.56, 95% CI: 0.39 to 0.81, *P*=0.002) [Figure 10B](#f10-anntransplant-23-524){ref-type="fig"}.

To assess the outcome measurement of 5-year DFS, a total of 8842 patients were included from 12 studies \[[@b16-anntransplant-23-524]--[@b18-anntransplant-23-524],[@b22-anntransplant-23-524],[@b26-anntransplant-23-524], [@b28-anntransplant-23-524],[@b30-anntransplant-23-524],[@b32-anntransplant-23-524]--[@b36-anntransplant-23-524]\]. The χ^2^ test revealed *P*=0.18 and I^2^=27%; meta-analysis using a fixed effect model revealed that the SLT group (41.27%) had superior 5-year DFS rate compared to the PLT group (47.09%), which was statistically significant (OR: 0.75, 95% CI: 0.66 to 0.86, *P*\<0.0001) [Figure 10C](#f10-anntransplant-23-524){ref-type="fig"}.

Data was classified according to donor type: DDLT and LDLT. SLT had superior 1-year, 3-year, and 5-year DFS rates compared to PLT in DDLT recipients: (OR: 0.77, 95% CI: 0.67 to 0.90, *P*=0.0006, [Figure 11A](#f11-anntransplant-23-524){ref-type="fig"}) \[[@b16-anntransplant-23-524]--[@b18-anntransplant-23-524],[@b26-anntransplant-23-524],[@b29-anntransplant-23-524],[@b30-anntransplant-23-524],[@b33-anntransplant-23-524],[@b35-anntransplant-23-524]--[@b37-anntransplant-23-524]\], (OR: 0.71, 95% CI: 0.62 to 0.81, *P*\<0.00001, [Figure 11B](#f11-anntransplant-23-524){ref-type="fig"}) \[[@b16-anntransplant-23-524]--[@b18-anntransplant-23-524],[@b22-anntransplant-23-524],[@b26-anntransplant-23-524],[@b29-anntransplant-23-524],[@b30-anntransplant-23-524],[@b33-anntransplant-23-524],[@b35-anntransplant-23-524]--[@b37-anntransplant-23-524]\], and (OR: 0.60, 95% CI: 0.53 to 0.69, *P*\<0.00001, [Figure 11C](#f11-anntransplant-23-524){ref-type="fig"}) \[[@b16-anntransplant-23-524]--[@b18-anntransplant-23-524],[@b22-anntransplant-23-524],[@b26-anntransplant-23-524],[@b30-anntransplant-23-524],[@b32-anntransplant-23-524],[@b33-anntransplant-23-524],[@b35-anntransplant-23-524]\], respectively. Similarly, SLT had better 1-year, 3-year, and 5-year DFS rates compared to PLT in LDLT recipients: (OR: 0.40, 95% CI: 0.21 to 0.77, *P*=0.006, [Figure 12A](#f12-anntransplant-23-524){ref-type="fig"}) \[[@b30-anntransplant-23-524],[@b32-anntransplant-23-524],[@b34-anntransplant-23-524]\] (OR: 0.52, 95% CI: 0.30 to 0.90*, P*=0.02, [Figure 12B](#f12-anntransplant-23-524){ref-type="fig"}) \[[@b30-anntransplant-23-524],[@b32-anntransplant-23-524],[@b34-anntransplant-23-524]\], and (OR: 0.55, 95% CI: 0.32 to 0.94*, P*=0.03, [Figure 12C](#f12-anntransplant-23-524){ref-type="fig"}) \[[@b30-anntransplant-23-524],[@b32-anntransplant-23-524],[@b34-anntransplant-23-524]\], respectively.

We further classified data according to Milan criteria: within Milan criteria and beyond Milan criteria. In patients within Milan criteria, there was no statistically significant difference for 1-year, 3-year, and 5-year DFS rates between SLT and PLT groups: (OR: 0.62, 95% CI: 0.22 to 1.78, *P*=0.37, [Figure 13A](#f13-anntransplant-23-524){ref-type="fig"}) \[[@b16-anntransplant-23-524],[@b18-anntransplant-23-524],[@b26-anntransplant-23-524],[@b27-anntransplant-23-524],[@b33-anntransplant-23-524],[@b35-anntransplant-23-524],[@b36-anntransplant-23-524]\], (OR: 0.60, 95% CI: 0.29 to 1.22, *P*=0.16, [Figure 13B](#f13-anntransplant-23-524){ref-type="fig"}) \[[@b16-anntransplant-23-524],[@b18-anntransplant-23-524],[@b22-anntransplant-23-524],[@b26-anntransplant-23-524],[@b27-anntransplant-23-524],[@b33-anntransplant-23-524],[@b35-anntransplant-23-524],[@b36-anntransplant-23-524]\], and (OR: 0.61, 95% CI: 0.32 to 1.19, *P*=0.15, [Figure 13C](#f13-anntransplant-23-524){ref-type="fig"}) \[[@b16-anntransplant-23-524],[@b18-anntransplant-23-524],[@b22-anntransplant-23-524],[@b26-anntransplant-23-524],[@b27-anntransplant-23-524],[@b33-anntransplant-23-524],[@b35-anntransplant-23-524],[@b36-anntransplant-23-524]\], respectively. There was not enough data to do meta-analysis of DFS for patients beyond the Milan criteria.

Postoperative outcomes
----------------------

### Biliary complication between SLT and PLT

To assess the outcome measurement of biliary complication, a total of 8172 patients were included from 9 studies \[[@b16-anntransplant-23-524],[@b17-anntransplant-23-524],[@b22-anntransplant-23-524],[@b23-anntransplant-23-524],[@b28-anntransplant-23-524],[@b30-anntransplant-23-524],[@b31-anntransplant-23-524],[@b34-anntransplant-23-524],[@b36-anntransplant-23-524]\]. The χ^2^ test revealed *P*=0.62 and I^2^=0%; meta-analysis using a fixed effect model revealed no statistically significant difference between SLT and PLT (OR: 1.14, 95% CI: 0.94 to 1.40, *P*=0.19) [Figure 14A](#f14-anntransplant-23-524){ref-type="fig"}.

### Sepsis between SLT and PLT

To assess the outcome measurement of sepsis, a total of 782 patients were included from 5 studies \[[@b17-anntransplant-23-524],[@b22-anntransplant-23-524],[@b23-anntransplant-23-524],[@b28-anntransplant-23-524],[@b36-anntransplant-23-524]\]. The χ^2^ test revealed *P*=0.99 and I^2^=0%; meta-analysis using a fixed effect model revealed no statistically significant difference between SLT and PLT (OR: 1.14, 95% CI: 0.63 to 2.06, *P*=0.68) [Figure 14B](#f14-anntransplant-23-524){ref-type="fig"}.

### Postoperative bleeding between SLT and PLT

To assess the outcome measurement of postoperative bleeding, a total of 8172 patients were included from 9 studies \[[@b16-anntransplant-23-524],[@b17-anntransplant-23-524],[@b22-anntransplant-23-524],[@b23-anntransplant-23-524],[@b28-anntransplant-23-524],[@b30-anntransplant-23-524],[@b31-anntransplant-23-524],[@b34-anntransplant-23-524],[@b36-anntransplant-23-524]\]. The χ^2^ test revealed *P*=0.25 and I^2^=21%; meta-analysis using a fixed effect model revealed SLT had higher rates of postoperative bleeding than that of PLT (OR: 1.32, 95% CI: 1.03 to 1.71, *P*=0.03) [Figure 14C](#f14-anntransplant-23-524){ref-type="fig"}.

### Vascular complications between SLT and PLT

To assess the outcome measurement of vascular complications, a total of 8172 patients were included from 9 studies \[[@b16-anntransplant-23-524],[@b17-anntransplant-23-524],[@b22-anntransplant-23-524],[@b23-anntransplant-23-524],[@b28-anntransplant-23-524],[@b30-anntransplant-23-524],[@b31-anntransplant-23-524],[@b34-anntransplant-23-524],[@b36-anntransplant-23-524]\]. The χ^2^ test revealed *P*=0.96 and I^2^=0%; meta-analysis using a fixed effect model revealed no statistically significant difference between SLT and PLT (OR: 1.35, 95% CI: 0.98 to 1.85, *P*=0.07) [Figure 14D](#f14-anntransplant-23-524){ref-type="fig"}.

### Operative mortality between SLT and PLT

To assess the outcome measurement of operative mortality, a total of 1738 patients were included from 12 studies \[[@b16-anntransplant-23-524],[@b17-anntransplant-23-524],[@b22-anntransplant-23-524],[@b23-anntransplant-23-524],[@b25-anntransplant-23-524],[@b27-anntransplant-23-524],[@b28-anntransplant-23-524],[@b31-anntransplant-23-524],[@b34-anntransplant-23-524]--[@b37-anntransplant-23-524]\]. The χ^2^ test revealed *P*=0.52 and I^2^=0%; meta-analysis using a fixed effect model revealed SLT had higher rates of operative mortality than that of PLT (OR: 2, 95% CI: 1.21 to 3.31, *P*=0.007) [Figure 14E](#f14-anntransplant-23-524){ref-type="fig"}.

Discussion
==========

PLT is a well-accepted ideal treatment strategy for patients with early stage HCC, but the lack of available organ donors requires the use of restrictive criteria to assure the optimal use of the available grafts. On the other hand, LR remains a valuable curative option for non-transplantable HCC patients or for those waiting for LT. However, the tumor recurrence rate is higher after LR within 5 years \[[@b38-anntransplant-23-524]\]. Thus, SLT after primary LR remains the ideal treatment for recurrent HCC and decompensated liver after primary LR \[[@b11-anntransplant-23-524],[@b15-anntransplant-23-524],[@b16-anntransplant-23-524]\]. Notwithstanding, the intensity of surgical difficulty during SLT and the potential for reduced OS is a concern for a large portion of experts. Substantial adhesions and portal collateral circulations are frequently experienced after earlier LR \[[@b16-anntransplant-23-524]\]. Likewise, because of adhesion, heedless dissection of adhesions around the liver may bring heavy bleeding at the dissection area. Moreover, because of adhesions, it's also hard to separate a hepatic vein and the inferior vena cava. However, some studies have demonstrated that SLT has similar perioperative and postoperative complications as that of the PLT \[[@b22-anntransplant-23-524],[@b23-anntransplant-23-524],[@b31-anntransplant-23-524]\]. Furthermore, reports suggest that meticulous sharp dissection with a sufficient dissection plan can resolve the problem of excessive bleeding in cases of excessive adhesions \[[@b23-anntransplant-23-524],[@b31-anntransplant-23-524]\]. Nevertheless, there are serious concerns among experts about the outcomes of SLT in comparison with the PLT, since most of the studies have reported conflicting results. However, there is still a need for a large multi-center study to compare the advantages and disadvantages of SLT and PLT.

Until now, few systematic reviews and meta-analysis have been conducted comprehensively to analyze the short-term and long-term outcomes of SLT and PLT. However, an earlier meta-analysis was reported but had only a few studies and had small total number of patients. Our meta-analysis includes 20 relatively high-quality studies conducted from 2003 to 2017, with a total 9879 patients (SLT=1306 and PLT=8573), thus we believe it is the first study of its type. In our meta-analysis, we found that SLT was superior and feasible in terms of OS and DFS compared to PLT, and we found that the incidence of postoperative complications, such as biliary complications, sepsis, and vascular complications of SLT were similar to that of PLT; however, there was a significantly higher rate of postoperative bleeding and operative mortality with the SLT group than the PLT group.

In the scenario of conflicting results from different studies, the most important finding regarding SLT was its post-transplant survival rate and DFS rate compared to PLT. Adam et al. \[[@b17-anntransplant-23-524]\] found that SLT was related to a higher risk of recurrence and a poorer outcome compared to PLT. Nonetheless, a study carried out in the same year by Belghiti et al. \[[@b22-anntransplant-23-524]\] found contrasting results and concluded that SLT and PLT were similar in term of OS rates. Moreover, a study by Scatton et al. \[[@b24-anntransplant-23-524]\] showed that careful consideration of histological features of resected tumor specimens may be used as selection criteria for SLT, with similar survival and recurrence result as PLT. As reported earlier by Adam et al. \[[@b17-anntransplant-23-524]\], the poor results after SLT were basically because of increased operative mortality and excess bleeding at the time of surgery, because of surgical difficulties during dissecting the substantial adhesions and portal collateral circulations during LT. However, the other studies have suggested that meticulous sharp dissection with a sufficient dissection plan can resolve the problem of excessive bleeding \[[@b23-anntransplant-23-524],[@b31-anntransplant-23-524]\].

As observed from pooled estimates of our meta-analysis, SLT showed superior 1-year, 3-year, and 5-year OS and DFS rates in comparison with PLT. After classifying data according to donor type, we found DDLT recipients showed no significant difference in 1-year and 3-year OS rates between the SLT and PLT groups. However, 5-year OS rates for DDLT recipients was superior in the SLT group compared to the PLT group. In LDLT recipients, SLT had superior 1-year, 3-year, and 5-year OS rates compared to PLT. Moreover, 1-year, 3-year, and 5-year DFS rates were also superior in SLT compared to PLT in both the DDLT and LDLT recipients. In addition, classifying data according to Milan criteria, our meta-analysis didn't find any difference for OS and DFS rates between the SLT and PLT groups for patients within the Milan criteria. The meta-analysis for OS beyond the Milan criteria was also not significant between SLT and PLT groups. SLT after LR has the advantage that surgeons are aware of the histological status of the tumor, which allows surgeons to choose appropriate patients for SLT. Currently, there are no definitive answers as to why the OS and DFS rates of SLT patients surpassed those of PLT patients. One possible explanation is that after primary liver resection, there is downstaging of the tumor, and the patients presenting for SLT are mostly patients with Child A, lower MELD score, lower AFP level, and fewer nodules compared to PLT patients \[[@b25-anntransplant-23-524],[@b26-anntransplant-23-524],[@b39-anntransplant-23-524]--[@b41-anntransplant-23-524]\]. Interestingly, when we compared MELD score and pre-transplant AFP levels between SLT and PLT groups, we found both MELD score and pre-transplant AFP levels were significantly lower in SLT patients than in PLT patients. Thus, the meta-analysis of MELD score and pre-transplant AFP levels seems to justify our findings, that SLT is superior to PLT in terms of OS and DFS. However, our meta-analysis showed the SLT group had a higher number of nodules, but smaller size of tumors compared to the PLT group. The reason for a higher number of nodules can be explained in 2 ways: 1) local recurrence and 2) de nova HCC, as LR is associated with high tumor recurrence because it leaves diseased liver in a place where local recurrence might be from insufficient R1 resection or micro-vascular invasion from segmental portal circulation. Furthermore, de nova HCC is still present in the diseased liver after LR, leading to distant recurrence from the resection area \[[@b42-anntransplant-23-524]\]. These 2 phenomena might be responsible for a higher number of nodules in the SLT group. However, regular monitoring of HCC patients after LR might be the result of smaller tumors in the SLT group compared to the PLT group. These results should be reevaluated according to the recent transplant selection requirements. Additionally, these findings also showed that the patient selection standard for SLT demands careful consideration and redefinition. Moreover, our review of studies suggested that along with tumor size and numbers of tumors, the liver transplantation could be implemented for less aggressive and pathological well differentiated tumors. This meta-analysis also showed that SLT is similar to PLT for patients within and beyond Milan criteria, and can be performed safely after LR.

Moreover, concern regarding postoperative outcomes between SLT and PLT results showed that the rate of postoperative complications like biliary, sepsis, and vascular complications, were similar among SLT and PLT patients; however, postoperative bleeding and operative mortality was significantly high in the SLT group compare to the PLT group. The possible causes of postoperative bleeding and operative mortality in SLT patients has already been discussed earlier in this article. Additionally, despite surgical difficulties in SLT, primary laparoscopic resection of the liver and postsurgical intra-abdominal anti-adhesive products are found to be effective in reducing adhesions and thereby minimizing the risks of complications in SLT \[[@b43-anntransplant-23-524],[@b44-anntransplant-23-524]\].

Despite the high quality of the papers included in this meta-analysis, there are various shortcomings concerning our meta-analysis. First, there is a potential publication bias, because studies are less likely to outline negative findings and there are limited resources available to identify unpublished trials. Second, only English-language studies were included. Thus, the quality of outcomes was compromised to some extent, which is a typical reason for publication bias. In the future, high quality randomized controlled trials with large sample size should be performed. However, this meta-analysis is still of great significance for comparing different outcomes between SLT and PLT and may prove beneficial for clinicians in choosing the appropriate treatment option.

Conclusions
===========

Compared with PLT, SLT had more postoperative bleeding and increased operative mortality. However, SLT was shown to have better 1-year, 3-year, and 5-year OS and DFS rates compared to PLT. As shown in the results of this meta-analysis of 9879 patients, SLT may be a better treatment strategy for recurrent HCC and for patients with compensated liver, whenever feasible, considering the severe organ limitation and the safety of SLT. However, PLT can be referred as a treatment strategy for HCC patients with cirrhotic and decompensated liver.
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###### 

Newcastle-Ottawa Quality Assessment Scale.

  Study                                             Selection   Comparability   Outcome   Overall                   
  ------------------------------------------------- ----------- --------------- --------- --------- --- --- --- --- ---
  Adam 2003 \[[@b17-anntransplant-23-524]\]         1           1               1         1         2   1   1   0   8
  Belghiti 2003 \[[@b22-anntransplant-23-524]\]     1           1               1         1         2   0   1   0   7
  Hwang 2007 \[[@b23-anntransplant-23-524]\]        1           1               1         1         2   0   0   0   6
  Scatton 2008 \[[@b24-anntransplant-23-524]\]      1           1               1         1         1   0   1   0   6
  Margarit 2005 \[[@b25-anntransplant-23-524]\]     1           1               1         1         1   0   1   0   6
  Del Gaudio 2008 \[[@b26-anntransplant-23-524]\]   1           1               1         1         2   0   1   1   8
  Wang 2016 \[[@b27-anntransplant-23-524]\]         1           1               1         1         2   0   0   1   7
  Liu 2012 \[[@b28-anntransplant-23-524]\]          1           1               1         1         1   1   0   1   7
  Facciuto 2008 \[[@b29-anntransplant-23-524]\]     1           1               1         1         1   0   0   1   6
  Hu 2012 \[[@b30-anntransplant-23-524]\]           1           1               1         1         2   0   1   0   7
  Cherqui 2009 \[[@b11-anntransplant-23-524]\]      1           1               1         1         2   0   1   0   7
  Kim 2008 \[[@b31-anntransplant-23-524]\]          1           1               1         1         2   0   0   1   8
  Vasavada 2015 \[[@b32-anntransplant-23-524]\]     1           1               1         1         2   0   1   1   8
  Wu 2012 \[[@b16-anntransplant-23-524]\]           1           1               1         1         2   0   1   1   8
  Bhangui 2016 \[[@b33-anntransplant-23-524]\]      1           1               1         1         2   0   1   1   8
  Moon 2012 \[[@b34-anntransplant-23-524]\]         1           1               1         1         2   0   1   1   8
  Sapisochin 2010 \[[@b35-anntransplant-23-524]\]   1           1               1         1         2   0   0   1   7
  Shan 2017 \[[@b18-anntransplant-23-524]\]         1           1               1         1         2   0   0   1   6
  Vennarecci 2007 \[[@b36-anntransplant-23-524]\]   1           1               1         1         2   1   0   0   7
  Shao 2008 \[[@b37-anntransplant-23-524]\]         1           1               1         1         2   0   0   0   6

###### 

Study characteristics included in meta-analysis.

  Study code   Study                                               Year   Country       Study type             Total N   Follow-up (mo)   Arms   n     Age (yrs)
  ------------ --------------------------------------------------- ------ ------------- ---------------------- --------- ---------------- ------ ----- -----------
  1            Adam et al. \[[@b17-anntransplant-23-524]\]         2003   France        Case-control           212       49±50            SLT    17    55.1±9.2
  51±46        PLT                                                 195    53.3±8.1                                                                     
  2            Belghiti et al. \[[@b22-anntransplant-23-524]\]     2003   France        Case-control           88        50.5±33          SLT    18    55±10
  50.5±33      PLT                                                 70     53±7                                                                         
  3            Hwang et al. \[[@b23-anntransplant-23-524]\]        2007   Korea         Case-control           217       30.7±26.8        SLT    17    49.3±8.6
  40.1±22.4    PLT                                                 200    51.2±7.0                                                                     
  4            Scatton et al. \[[@b24-anntransplant-23-524]\]      2008   France        Retrospective cohort   93        45.6±52.8        SLT    20    53.5±8
  32.4±54      PLT                                                 73     \<70                                                                         
  5            Margarit et al. \[[@b25-anntransplant-23-524]\]     2005   Spain         Retrospective cohort   42        50               SLT    6     62±6
  44           PLT                                                 36     59.9±7.6                                                                     
  6            Del Gaudio et al. \[[@b26-anntransplant-23-524]\]   2008   Italy         Retrospective cohort   163       26.2±26.3        SLT    16    54±8
  36±32        PLT                                                 147    55±7                                                                         
  7            Wang et al. \[[@b27-anntransplant-23-524]\]         2016   China         Retrospective cohort   371       19.5±24.4        SLT    76    48.5±8.6
  19.5±24.4    PLT                                                 295    48.3±8.5                                                                     
  8            Liu et al. \[[@b28-anntransplant-23-524]\]          2012   China         Retrospective cohort   219       30±20.25         SLT    39    44
  33±22        PLT                                                 180    47                                                                           
  9            Facciuto et al. \[[@b29-anntransplant-23-524]\]     2008   USA           Retrospective cohort   37        27.75±18.77      SLT    5     \<70
  35±33        PLT                                                 32     \<70                                                                         
  10           Hu et al. \[[@b30-anntransplant-23-524]\]           2012   China         Retrospective cohort   6975      12.2±4.4         SLT    888   50.0±9.28
  12.4±4.2     PLT                                                 6087   49.7±9.67                                                                    
  11           Cherqui et al. \[[@b11-anntransplant-23-524]\]      2009   France        Retrospective cohort   154       \>5 years        SLT    18    \<70
  \>5 years    PLT                                                 136    \<70                                                                         
  12           Kim et al. \[[@b31-anntransplant-23-524]\]          2008   South Korea   Retrospective cohort   46        18.3±8           SLT    15    48.1±7
  18.7±7.2     PLT                                                 31     51.2±6.2                                                                     
  13           Vasavada et al. \[[@b32-anntransplant-23-524]\]     2015   India         Retrospective cohort   109       31               SLT    18    56±5
  31           PLT                                                 91     56±6                                                                         
  14           Wu et al. \[[@b16-anntransplant-23-524]\]           2012   China         Retrospective cohort   183       58.7±20.7        SLT    36    49.46±7.1
  64.2±18.1    PLT                                                 147    47.66±5.8                                                                    
  15           Bhangui et al. \[[@b33-anntransplant-23-524]\]      2016   France        Retrospective cohort   371       \>5 years        SLT    31    \<65
  \>5 years    PLT                                                 340    \<65                                                                         
  16           Moon et al. \[[@b34-anntransplant-23-524]\]         2012   Korea         Retrospective cohort   186       27.2±21.7        SLT    17    51
  39±18.8      PLT                                                 169    52                                                                           
  17           Sapisochin et al. \[[@b35-anntransplant-23-524]\]   2010   Spain         Case-control           51        88.9±47.5        SLT    17    59
  88.9±47.5    PLT                                                 34     62                                                                           
  18           Shan et al. \[[@b18-anntransplant-23-524]\]         2017   China         Retrospective cohort   239       35±10.2          SLT    28    47.79±.64
  35±6.8       PLT                                                 211    50.45±9.24                                                                   
  19           Vennarecci et al. \[[@b36-anntransplant-23-524]\]   2007   Italy         Retrospective cohort   46        28.5±17.1        SLT    9     \<70
  26.3±14.8    PLT                                                 37     \<70                                                                         
  20           Shao et al. \[[@b37-anntransplant-23-524]\]         2008   China         Retrospective cohort   77        18±3.4           SLT    15    \<60
  21±4.5       PLT                                                 62     \<60                                                                         
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